Hospital Melaka

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Obesity5 trials
• Type 2 diabetes4 trials
• Chronic kidney disease3 trials
• Psoriasis1 trial
• Psoriatic arthritis1 trial

Phase

• Phase 38 trials
• Phase 22 trials

Status

• Active, not recruiting3 trials
• Withdrawn3 trials
• Completed2 trials
• Not yet recruiting2 trials

Lead sponsor

• Novo Nordisk A/S7 trials
• Boehringer Ingelheim2 trials
• Janssen Research & Development, LLC1 trial

Running trials

• Not yet recruiting

  AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

  NCT07668401· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  NCT06717698· Phase 2· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting

Closed trials

• Withdrawn

  A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

  NCT07357740· Phase 2· Novo Nordisk A/S· Source

• Withdrawn

  A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

  NCT07357766· Phase 3· Novo Nordisk A/S· Source

• Withdrawn

  Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

  NCT06083675· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

  NCT05394519· Phase 3· Novo Nordisk A/S· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source